GSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop messenger RNA vaccines that could protect against the novel coronavirus and other infectious diseases.
Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
GSK Plc (NYSE:GSK) shelved on Wednesday its herpes simplex virus (HSV) vaccine development program. The recombinant protein vaccine, dubbed GSK3943104, did not meet the study’s primary efficacy ...
Wednesday, GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) announced they have restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize ...
GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks for a new generation of immunotherapy medicines. Interim analysis from two ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results